STRO

#2802
Sutro Biopharma, Inc.
35.8000 USD
+6.58%
Setor: Cuidados de saúde
Base: USD
Moeda do lucro: USD
Faixa diária
35.6777
35.9500
Faixa anual
16.7400
36.0000
Mudança diária
+6.58%
Mudança mensal
+46.54%
Mudança em 6 meses
+105.87%
Mudança anual
+105.87%
Fechamento anterior
33.5900
Abrir
35.9500
Mínimo
35.6777
High
35.9500
Volume
5
Abrir gráfico completo

Financials

Visão geral Relatórios Estatísticas
Trimestral Ano
  • Market Capitalization 593.1071 M
  • Employee 137
  • Founded 2003
  • CEO N/A
  • Website www.sutrobio.com
  • Headquarter California, United States
  • FIGI BBG000R4V3P3
  • Industry Biotecnologia
Receita total
Lucro líquido
Lucro básico por ação
Dívida total
Fluxo de caixa livre
Caixa e equivalentes de caixa
Índice preço/lucro
-0.51
Índice preço/fluxo de caixa
0.96

Sutro Biopharma Inc

Sutro Biopharma, Inc. is a publicly traded biotechnology company headquartered in South San Francisco, California focused on clinical-stage drug discovery, development and manufacturing. Using a proprietary cell-free protein synthesis platform, Sutro is working on oncology therapeutics using protein engineering and rational design. Founded in 2003 under the name Fundamental Applied Biology, the company name changed to Sutro Biopharma in 2009. William Newell, CEO as of 2024, joined Sutro in January 2009. Sutro's cell-free protein synthesis and site-specific conjugation platform, XpressCF+, contributed to the discovery of STRO-001 and STRO-002, internally-developed antibody drug conjugates, or ADCs. STRO-001 is an ADC targeting CD74, a protein highly expressed in multiple myeloma and non-Hodgkin's lymphoma, and is currently in a Phase I clinical trial. STRO-002 is an ADC targeting folate receptor alpha, a cell-surface protein highly expressed in gynecological cancers.

Notícias